Evolus, Inc.

EOLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-51.6M $-50.4M $-61.7M $-74.4M $-46.8M $-163.0M $-90.0M $-46.9M
Depreciation & Amortization $7.5M $5.3M $5.1M $3.7M $5.6M $7.0M $4.1M $9.0K
Depreciation $1.2M $1.2M $1.0M $373.0K — — — —
Amortization $6.3M $4.1M $4.1M $3.4M $5.3M $3.6M $3.9M $0
Stock-Based Compensation $20.7M $22.3M $16.5M $10.8M $9.6M $10.6M $9.5M $7.0M
Net Cash from Operating Activities $-42.3M $-18.0M $-34.0M $-84.9M $-33.4M $-57.9M $-93.4M $-25.7M
Investing Activities
Capital Expenditures $3.4M $1.5M $473.0K $1.6M $393.0K $815.0K $345.0K $9.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-8.5M $-4.8M $-1.6M $-2.9M $4.0M $12.2M $-23.4M $-9.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $17.3M $47.4M $44.6M $-4.1M $73.1M $38.3M $133.5M $118.8M
Net Change in Cash $-33.1M $24.1M $8.9M $-92.3M $43.7M $-7.3M — $93.2M
Free Cash Flow $-45.7M $-19.5M $-34.5M $-86.5M $-33.8M $-58.7M $-93.7M $-25.7M
← Newer Page 1 of 2 Older →